Background: The prognosis of patients with systemic lupus erythematosus (SLE) largely depends on the severity of cumulative organ damage during the course of the disease. While Sjùgren's syndrome (SS) predominantly affects exocrine glands, a considerable number of patients develop visceral organ damage. Thus, the occurrence of a secondary SS (2°SS) in SLE patients, may result in more extensive organ damage and thereby adversely affect prognosis.
Patients/Methods: 138 patients meeting the 1982 American College of Rheumatology (ACR) classification criteria for SLE were prospectively studied over a mean period of ninety months. 2°SS was diagnosed according to the 1993 European Study Group criteria and complication rates and prognosis were compared between patients with and without SS.
Results: 27 patients (19%) developed SS after a mean period of 48 months. There was a gradual increase in SS prevalence over time after SLE-onset. 2°SS patients were older (mean age 41 vs 35 years, P = 0.03), had less renal disease (19% vs 38%, P = 0.04), more thrombocytopenia (26% vs 9%, P = 0.05) and similar serological profiles (including anti-SSa) as patients without SS. Overall mortality was lower in patients with SS (4% vs 13.5%, P = 0.01), while lifetable analysis showed improved survival estimates for 2°SS patients with borderline statistical significance (P = 0.06).
Conclusions:2SS develops in about one-fifth of SLE patients in a time-dependent fashion: these patients are older, have less renal involvement and their prognosis is at least as good as for those remaining free of SS.
Fox RI.Clinical features, pathogenesis and treatment of Sjùgren's syndrome . Curr Opin Rheumatol1996; 8: 438–445 .
2.
Moutsopoulos HM et al. Sjùgren's syndrome (sicca syndrome): current issues . Ann Int Med1980; 92: 212–226 .
3.
Manthorpe R , Asmussen K , Oxholm P . Primary Sjùgren's syndrome: diagnostic criteria, clinical features and disease activity . J Rheumatol1997; 24(S50): 8–11 .
4.
Fox RI.Pathogenesis and treatment of Sjùgren's syndrome . Curr Opin Rheumatol1997; 9: 393–399 .
5.
Boumpas DT et al. Systemic Lupus Erythematosus: merging concepts . Part 2. Ann Intern Med1995; 123: 42–53 .
6.
Tan EM , Cohen AS , Fries JF . The 1982 revised ARA-criteria for the classification of systemic lupus erythematosus . Arthritis Rheum1982; 25: 1271–1277 .
7.
Swaak AJG , Nossent JC , Bronsveld W , van Rooyen A , Nieuwenhuys EJ , Theuns L . Systemic Lupus Erythematosus. II. Observations on the occurrence of exacerbations in the disease course: Dutch experience with 110 patients studied prospectively . Ann Rheum Dis1989; 48: 455–460 .
8.
Vitali C , Bombardieri S , Moutsopoulos HM . Preliminary criteria for the classification of Sjùgren's syndrome. Results of a prospective concerted action supported by the European Community . Arthritis Rheum1993; 36: 340–347 .
9.
Nossent JC et al. Relation between serological data at the time of biopsy and renal histology in lupus nephritis . Rheum Int1991; 11: 77–82 .
10.
Harris EN , Gharavi E , Patel SP , Hughes GRV . Evaluation of the anticardiolipin antibody test: report of an international workshop held in April 1986 . Clin Exp Immunol1987; 68: 215–222 .
11.
Heaton JM . Sjùgren's syndrome and Systemic Lupus Erythematosus . BMJ1959; 1: 466–469 .
12.
Utset TO et al. Depressive symptoms in patients with systemic lupus erythematosus: association with central nervous system lupus and Sjùgren's syndrome . J Rheumatol1994; 21: 2039–2045 .
13.
Vlachoyiannopoulos PG , Karassa FB , Karakostas KX , Drosos AA , Moutsopoulos HM . Systemic lupus erythematosus in Greece. Clinical features, evolution and outcome: a descriptive analysis of 292 patients . Lupus1993; 2: 303–312 .
14.
Andonopoulos AP , Skopouli FN , Dimou GS , Drosos AA , Moutsopoulos HM . Sjùgren's syndrome in systemic lupus erythematosus . J Rheumatol1990; 17: 201–204 .
15.
Jonsson H , Nived O , Sturfelt G . Outcome in Systemic Lupus Erythematosus: A prospective study of patients from a defined population . Medicine1989; 68: 141–150 .
16.
Grennan DM et al. Sjùgren's syndrome in SLE: part I The frequency of the clinical and subclinical features of Sjùgren's syndrome in patients with SLE . NZ Med J1977; 86: 374–376 .
17.
Alarcon-Segovia D , Ibanez G , Velasquez-Forero F , Hernandez-Ortiz J , Gonzales-Jimenez Y . Sjùgren's syndrome in Systemic Lupus Erythematosus. Clinical and subclinical manifestations . Ann Int Med1974; 81: 577–583 .
18.
Kassan SS , Talal N . Sjùgren's syndrome with Systemic Lupus Erythematosus/Mixed Connective Tissue Disease. In: Kassan SS , Moutsopoulus HM , Talal N (eds). Sjùgren's syndrome. Clinical and immunological aspects. Springer-Verlag: Heidelberg , 1987, pp 178–181.
19.
Jonsson H , Nived O , Sturfelt G . The effect of age on clinical and serological manifestations in unselected patients with systemic lupus erythematosus . J Rheumatol1988; 15: 505–509 .
20.
Cervera R et al. Antiphospholipid antibodies in primary Sjùgren's; syndrome: prevalence and clinical significance in a series of 80 patients . Clin Exp Rheum1997; 15: 361–365 .
21.
Kruize AA , Hene RJ , van der Heide A . Long-term follow-up of patients with Sjùgren's syndrome . Arthritis Rheum1996; 39: 297–303 .
22.
Steinberg AD , Talal N . The coexistence of Sjùgren's syndrome and Systemic Lupus Erythematosus . Ann Int Med1971; 74: 55–61 .
23.
Reveille JD , Bartolucci A , Alarcon GS . Prognosis in Systemic Lupus Erythematosus. Negative impact of age at onset, black race and thrombocytopenia, as well as causes of death . Arthritis Rheum1990; 33: 37–48 .
24.
Bell DA.SLE in the elderly—is it really SLE or Systemic Sjùgren's syndrome?J Rheumatol1988; 15: 723–724 .
